Overview

Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension
Phase:
PHASE4
Details
Lead Sponsor:
Jing Liu
Treatments:
Amlodipine
Calcium Channel Blockers
sacubitril